𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reduced occurrence of mdr-1 amplification in stage-IV breast-cancer patients treated with tamoxifen compared with other endocrine treatments

✍ Scribed by Ulf Lönn; Sigrid Lönn; Björn Stenkvist


Publisher
John Wiley and Sons
Year
1993
Tongue
French
Weight
496 KB
Volume
53
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Amplification of mdr‐1 occurs in breast cancer patients receiving endocrine treatment. We have compared a group of patients receiving tamoxifen and a group receiving second‐line endocrine treatment after failure of tamoxifen treatment. Chronological tumor samples were obtained by fine‐needle biopsies from the same tumor lesion of each patient and PCR was used to detect the appearance of gene amplification. Three of 20 patients receiving tamoxifen developed amplified mdr‐1 whereas 7 of 17 patients receiving second‐line endocrine treatment developed mdr‐1 amplification.